Sightful Invest
  • Business
  • Investing
  • Politics
  • Stock
Top Posts
Trump lashes out at Crockett, renews call for...
Trump goes after Zelenskyy over ‘land swapping’ dispute,...
Democratic whistleblower told FBI that Adam Schiff approved...
MORNING GLORY: Trump meets Putin amid an era...
‘Things need to change’: Senate Democrats sharpen criticism...
Mamdani zings Cuomo in rent-stabilized housing spat during...
Unearthed emails reveal White House nixed Biden visiting...
Strong drilling targets identified next to high-grade gold-copper...
Seymour Lithium Project Achieves Permitting Milestone
Acquisition of Silver Extraction Technology
  • Business
  • Investing
  • Politics
  • Stock

Sightful Invest

Politics

FDA chief counsel who defended abortion pill under Biden resigns 2 days into job

by admin March 13, 2025
March 13, 2025
FDA chief counsel who defended abortion pill under Biden resigns 2 days into job

The Food and Drug Administration’s (FDA) top lawyer, who was appointed to the position just this week, has resigned, according to a Thursday morning post on X.

‘Hilary K. Perkins has resigned from her position as Chief Counsel of FDA, effectively immediately,’ the FDA’s official X account posted.  

Perkins – a former assistant director under Biden’s Department of Justice (DOJ) in the consumer protection agency – was selected on Tuesday by acting general Sean Keveney in the Department of Health and Human Services (HHS) as part of a ‘reorganization’ effort by the department, according to an HHS news release.

She previously defended abortion pill access in a high-profile case under Biden’s DOJ, and HHS officials were reportedly unhappy with the decision to appoint Perkins but were overruled by White House officials, according to a report from Axios this week.

‘We’ve been able to recruit higher quality personnel to HHS than in any time in its history,’ HHS Secretary Robert F. Kennedy, Jr., said in a statement Tuesday at the announcement of Perkins’ assignment on Tuesday. ‘These are individuals who will return the agency to gold-standard science, evidence-based medicine, and recalibrate its trajectory toward public health rather than industry profiteering.’

Fox News Digital has reached out to the HHS and FDA for comment.

This is a breaking story, check back for updates.

This post appeared first on FOX NEWS

previous post
Brian Leni: Latest Mining Stock Wins and How I’m Deploying Cash Now
next post
Senate Republicans coin ‘Schumer shutdown’ ahead of critical vote on Trump spending bill

You may also like

DAVID MARCUS: Trump’s tariff triumph big step for...

April 10, 2025

SCOOP: Inside progressives’ plan to have ‘thousands’ protest...

April 25, 2025

Pentagon bracing for sweeping changes after Trump nominates...

November 18, 2024

House DOGE subcommittee chair Greene threatens criminal referrals...

February 27, 2025

Iran foreign minister vows nuclear enrichment will continue...

May 19, 2025

Argentina’s Milei rallies Venezuelan opposition despite Maduro’s ‘ugly’...

August 4, 2024

Flashback: Harris proposed middle class tax increase for...

August 1, 2024

Tulsi Gabbard changes tune on controversial intelligence tool...

January 11, 2025

New polls reveal which White House term showed...

March 4, 2025

Greenland’s center-right party pulls off upset victory as...

March 12, 2025

Recent Posts

  • Trump lashes out at Crockett, renews call for cognitive test
  • Trump goes after Zelenskyy over ‘land swapping’ dispute, lays out ‘feel out meeting’ with Putin
  • Democratic whistleblower told FBI that Adam Schiff approved classified leaks to target Trump
  • MORNING GLORY: Trump meets Putin amid an era done away with John Quincy Adams’ ‘abroad’
  • ‘Things need to change’: Senate Democrats sharpen criticism of Israel as humanitarian concerns grow

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Categories

    • Business (867)
    • Investing (2,729)
    • Politics (3,369)
    • Stock (4)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sightfulinvest.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 Sightful Invest. All Rights Reserved.